1
Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer
Condition(s):Breast CancerLast Updated:February 28, 2020Unknown status
Palbociclib: 344 Clinical Trials, Page 1 of 35
Hide Studies Not Open or Pending
2
Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy
Condition(s):Breast CancerLast Updated:October 25, 2022Completed
3
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
Condition(s):Triple Negative Breast Cancer; Locally Advanced Breast Cancer; Recurrent Breast Cancer; Metastatic Breast Cancer; ER+ Breast Cancer; HER2-positive Breast CancerLast Updated:January 9, 2023Recruiting
4
Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent Thromboinflammation
Condition(s):COVID-19Last Updated:November 7, 2022Withdrawn
5
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer
Condition(s):Cancer, AdvancedLast Updated:June 21, 2018Withdrawn
6
Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate
Condition(s):Advanced Breast Cancer FemaleLast Updated:January 20, 2022Completed
7
A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)
Condition(s):Pancreatic Neuroendocrine CancerLast Updated:January 23, 2018Completed
8
Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)
Condition(s):Breast Cancer FemaleLast Updated:June 29, 2022Completed
9
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
Condition(s):Breast CancerLast Updated:March 23, 2022Active, not recruiting
10
Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer.
Condition(s):Ovarian CancerLast Updated:February 11, 2022Active, not recruiting